Inauguration of the new ACIST European Headquarters

Heerlen, the Netherlands , 01/22/2016

ACIST Medical Systems has inaugurated its new European headquarters, combining the Maastricht offices and the Sittard assistance center and distribution facility into one large site that is spread over about 10,000 square meters in the Trilandis Business Park in Heerlen. ACIST Medical Systems is an American company based in Minnesota that was acquired by Bracco in 2001 and is now the world leader in solutions for the controlled administration of contrast agents in cardiology, with subsidiaries in Europe and Asia (among which Japan and China).

Over 1 million people annually undergo cardiovascular angiographic procedures using ACIST solutions and that number is set to grow. ACIST’s systems, widely utilized in the most advanced medical fields, are today installed in clinics all over the world, including many internationally recognized centers of excellence, hospitals and university institutes. In addition to the contrast delivery system (CVi) already being used in more than 70 countries worldwide, ACIST’s portfolio has been recently broadened to include the Rapid Exchange FFR (RXi) and HD-IVUS (HDi) systems.

“The opening of this new European headquarters is a bridge that will bring ACIST into the future”, affirmed Fulvio Renoldi Bracco, Head of the Global Business Unit Imaging of the Bracco Group and Chairman of ACIST. “A future that we can look towards with confidence thanks to our state-of-the-art research laboratories, and to our employees’ capabilities and ability to innovate.”

“ACIST Medical Systems plays a strategic role for Bracco”, added Fulvio Renoldi Bracco “inasmuch as, through its recently enhanced portfolio, it has positioned itself as a leading provider of solutions for advanced diagnostics and intervention in the cardiovascular field.”

“Driven by continuing Acist growth, we have decided to move our European headquarters into a new, larger site”, said Thomas Morizio, President and CEO of ACIST Medical Systems. “Through this modern, beautiful facility we will serve the whole EMEA market. Thanks to our pioneering technology we expect to keep growing and maintain our leadership in cardiological medical treatments”.